Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Esophageal Neoplasms 11Pancreatic Neoplasms 7Cholangiocarcinoma 6Liver Neoplasms 5Colonic Neoplasms 4Neoplasms 3Colorectal Cancer Metastatic 3Spinocerebellar Degenerations 2Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Liver Diseases 2Gastric Adenocarcinoma 2Advanced Biliary Tract Cancer 2Uterine Cervical Neoplasms 1Unresectable Locally Advanced Pancreatic Cancer 1Turcot syndrome 1Tislelizumab 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1PD-1 Antibody 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Microsatellite Stable Metastatic Colorectal Cancer 1

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × sintilimab × Gastrointestinal × Clear all
NCT04300959 2020-03-09

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Zhejiang Cancer Hospital

Phase 2 Unknown
80 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡